

Index

- ACE inhibitors, 26
 acetaminophen, *see* paracetamol
 acupressure, anti-emetic effect, 143
 acute drugs, 64–5
 adenoidectomy, 161
 adrenaline, 64
 α -2-chloroprocaine, 74, 81
 age impact on patient selection, 18–20
 agitation, postoperative, 147
 airway disease, 20–1
 ASA III pulmonary/airway disease patients, 91
 preoperative information, 31
 alcohol abuse, 25–6
 anesthesia and, 95–6
 alfentanil, 51, 59, *see also* opioids
 allergies, 29
 anesthesia and, 98
 preoperative information, 32
 α 2-adrenergic receptor agonists, 121–2
 ambulatory surgery
 definitions, 1–2
 economy, 5
 future aspects, 178–9
 history, 2–3
 organization, 7–10
 procedures, 16
 quality, 4–5
 reasons for, 3
 safety, 3–4
 staff satisfaction, 6
 success criteria, 176–8
 ambulatory unit
 as satellite of inpatient hospital, 9
 documentation, 13–14
 equipment, 12
 freestanding hospital, 9–10
 freestanding office-based, 10
 freestanding unit inside inpatient hospital, 9
 integration into inpatient hospital, 8
 optimal size, 10–11
 personnel, 12–13
 physical requirements, 11–12
 analgesia *see also* postoperative pain; *specific analgesics*
 multimodal, 109
 nonopioid analgesics, 107, 109–24
 opioids, 109
 pre-emptive, 106–7, 126
 anesthesia *see also* general anesthesia; local anesthesia; regional anesthesia
 acute disease and, 96
 alcohol/drug abuse and, 95–6
 allergy and, 98
 ASA III pulmonary/airway disease patients, 91
 breastfeeding patients, 96
 cardiovascular disease patients, 91–3
 children, 88–90, 159–61
 choice of technique, 87–8
 diabetic patients, 95
 elderly patients, 90–1
 epileptic patients, 97–8
 future aspects, 178–9
 history, 12–13
 information for patient, 33–4
 kidney disease and, 97
 liver disease and, 97
 neurologic diseases and, 97
 obese patients, 93–5
 pregnant patients, 96
 preoperative information, 32
 problems with, 29, 98
 psychiatric patients, 96
 rheumatic conditions, 97
 success criteria, 176–8
 thyroid disorders and, 97
 anesthetic report, 14
 angina pectoris, 22
 anesthesia and, 92
 angiotensin blockers, 26
 ankylosing spondylitis, *see* Bechterew disease
 anti-asthmatics, 26–7
 anticholinergics, 143
 anticoagulants, preoperative, 98–9
 anticoagulated patients, 23–4
 loco-regional techniques and, 78
 anti-emetic drugs, 140–1
 anticholinergics, 143
 antihistamines, 143
 ephedrine, 143
 glucocorticoids, 142–3
 metoclopramide, 141–2
 neuroleptics, 142
 NK1 inhibitors, 143
 serotonin antagonists, 142
 antihistamines, 143
 antineuropathics, 120–1
 antiplatelet therapy, 23
 anxiety, postoperative, 147
 aortic insufficiency, 23
 anesthesia and, 92
 arrhythmia, 23
 articaine, 74, 81
 ASA classification, 18
 asthma, 91
 anti-asthmatics, 26–7
 children, 19
 preoperative information, 31
 atropine, 64
 AV block, 23
 awake patient during procedure, 72
 barbiturates, 58
 Bechterew disease, 28–9
 anesthesia, 97
 bed rest, 5
 benzodiazepine antagonists, 64
 benzodiazepines
 sedation, 86
 side-effects, 50
 beta-blockers, 27, 64, 166
 bispectral index (BIS), 87
 BIS monitoring, 169
 body mass index (BMI), 24–5
 bodybuilders, 26

Index

- bradycardia, 64
 breastfeeding patients, 28
 anesthesia, 96
 bupivacaine, 80
- calcium channel blockers, 120–1
 cannabinoids, 122–3
 cardiovascular disease, 91–3
 anesthesia and, 91–3
 children, 18–19
 anesthesia, 88–90, 159–61
 asthma, 19
 ENT procedures, 160–1
 paracetamol use, 110–11
 runny nose, 19
 sedation, 88
 sleep apnea syndrome, 19
 target control infusion
 models, 56
- 2-chloroprocaine
 cholesterol-lowering drugs, 27
 chronic obstructive pulmonary
 disease (COPD), 91
 obese patients, 93
 circulatory side-effects, 50
 cisatracurium, 71
 clearance, 39, 44
 clonidine, 80, 122
 codeine, 60–1
 cognitive dysfunction, 4
 anesthesia and, 96
 loco-regional technique
 benefits, 72
 patient selection, 27
 complications *see also*
 side-effects
 information for patient, 33,
 34–5
 context sensitive elimination
 time, 46
 coronary infarction, 22
 anesthesia and, 92
 cost-efficacy, 177
 COX inhibitors, 113–14
 cyclooxygenase (COX), 113–14
- dental surgery, 162
 depth of anesthesia monitoring
 (DAM), 168–70
 desflurane, 57, 69 *see also*
 inhalational drugs
 children, 90
 pharmacodynamics, 41–2
- pharmacokinetics, 40–1
 dexamethasone, 116–18 *see also*
 glucocorticoids
 peroperative administration,
 126
 side-effects, 118
 dexmedetomidine, 59, 73, 167
 sedation, 87
 diabetes mellitus, 25
 anesthesia and, 95
 preoperative information, 31
 diazepam, 58, 73
 discharge, 149–50
 criteria, 15–16, 149–9
 information for patient,
 149–50
 post-discharge care, 150–1
 distribution volume, 38, 44
 documentation, 13–14
 droperidol, 80, 142
 drug abuse, 25–6
 anesthesia and, 95–6
 bodybuilders, 26
 drug metabolism, 39 *see also*
 pharmacology
- economy, 5
 cost-efficacy, 177
 loco-regional techniques, 73
 education, 6
 effect-site target control infusion
 (TCI) system, 53–4
 versus plasma TCI system, 55
 elderly patients, 19–20
 anesthesia, 90–1
 electrostimulation, anti-emetic
 effect, 143
 emergencies, 6, 11
 acute drugs, 64–5
 emergency equipment, 12
 emergency surgery, 15
 endotracheal (ET) tube,
 171, 172
 ENT procedures, children,
 160–1
 ephedrine, 64, 143
 epidural anesthesia, 78–9
 epilepsy, 29
 anesthesia and, 97–8
 preoperative information, 31
 epinephrine, 122
 equipment, 12
 loco-regional techniques, 74
- esmolol, 64
 eye surgery, 162
- facial mask, 170
 fast-tracking, 73
 fentanyl, 51, 59, 70 *see also*
 opioids
 interactions, 43
 foot surgery, 81–2
- gabapentin, 120–1
 gastric tubes, 140
 gastro-oesophageal reflux
 disease, obese patients, 93
 general anesthesia, 12–13, 88
 general, 68
 inhalational anesthesia, 68–9
 intravenous anesthesia,
 69–70
 obese patients, 94–5
 glucocorticoids, 115–19
 analgesic action, 116–19
 anti-emetic effects, 142–3
 clinical actions, 116, 118
 effect mechanisms, 115
 molecular actions, 115–16
 peroperative administration,
 125–6
 preoperative, 99
 side-effects, 118
 glycopyrrolate, 62–3
- heart block, 23
 heart failure, 23
 anesthesia and, 92
 heart valve dysfunction, 23
 anesthesia and, 92
 hepatic disease *see* liver disease
 hospital-acquired infection, 4
 hyperalgesia, 60, 64, 70
 prevention, 106, 126
 hypertension, 22
 anesthesia and, 91–2
 preoperative information, 31
 hypnotics, 42, 58–9 *see also*
 intravenous drugs
 interactions, 50–2
 sedation, 87
 side-effects, 50
 hypotension, 64
- immobility, 5
 infants *see* newborn infants

Index

- infection
 as contraindication for loco-regional techniques, 78
 preoperative information, 31
 respiratory infections, 20
 risk of, 4
- information for patient, 32–5
 anesthesia plan, 33–4
 discharge, 149–50
 logistics, 34
 side-effects, 33, 34–5
- inguinal hernia repair, 83
- inhalational anesthesia *see also*
 inhalational drugs
 benefits of, 167
 induction, 158–9, 168
 maintenance, 168
 recipes, 156–9
 versus intravenous
 anesthesia, 165
- inhalational drugs, 56–7, 68–9,
 see also specific drugs
 children, 160
 interactions with intravenous
 agents, 42–3
 pharmacodynamics, 41–2
 pharmacokinetics, 39–41
- inpatient hospital
 ambulatory programme as
 fraction of, 8
 ambulatory unit as satellite, 9
 ambulatory unit integration, 8
 freestanding ambulatory unit
 within, 9
 single ambulatory patient
 integration, 7
- insulin *see* diabetes mellitus
- intra-cardiac defibrillator
 (ICD), 92–3
- intralipid, 65
- intravenous anesthesia *see also*
 intravenous drugs
 controversies, 164–7
 recipes, 152–9
- intravenous drugs, 69–70 *see*
 also hypnotics; opioids;
 specific drugs
 interactions, 42–3, 50–2
 pharmacodynamics,
 46–50
 pharmacokinetics, 43–6
 regional anesthesia, 83
- intubation, 70–1, 171, 172
- isoflurane, 57
 pharmacodynamics, 41–2
 pharmacokinetics, 40–1
- joints, local anesthetic
 infusion, 74
- k_{eo} , 47
- ketamine, 63–4, 166
 children, 161
 postoperative pain
 management, 64, 119–20
- ketorolac, 113–14
- kidney disease, 28
 anesthesia and, 97
- laparoscopy, 161
- laryngeal mask airway (LMA),
 70, 170–2
- levobupivacaine, 74
- lidocaine
 postoperative pain
 management, 120–1
 transient neurologic
 symptoms and, 79–80
- liver disease, 28
 anesthesia and, 97
- local anesthesia, 13, 71–3, 77, 88
 see also loco-regional
 techniques
 definition, 71
 infusion into wounds or
 joints, 74
 postoperative pain
 management, 110
 procedures, 76–7
- loco-regional techniques, 71,
 83–4 *see also* local
 anesthesia; regional
 anesthesia
 acceptance by patient, 75
 acceptance by surgeon, 75
 block failure avoidance, 76
 contraindications, 78
 economy, 73
 elderly patients, 91
 equipment, 74
 local infiltration, 84
 new drugs, 74
 new techniques, 74–5
 obese patients, 94
 preoperative delay
 avoidance, 75–6
- prolonged block avoidance,
 76
 quality, 72–3
 safety, 72
- magnesium, 123–4
- medications
 drug history, 32
 patient selection and,
 26–7
- membrane stabilizing drugs,
 120–1
- methohexital, 58, 166
- methylnaltrexone, 143
- methylprednisolone, 116, 117
 see also glucocorticoids
- metoclopramide, 141–2
- metoprolol, 64
- mexiletine, 120–1
- midazolam, 58, 73
 interactions, 43, 58
- mitral insufficiency, 23
 anesthesia and, 92
- mivacurium, 62, 71
- mobilization, 5
- monitored anesthesia care
 (MAC), 71
- monitoring
 depth of anesthesia
 monitoring (DAM),
 168–70
 equipment, 12
 sedation, 87
- multimodal analgesia, 109
- myringotomy, 160
- nalbuphine, 80
- naloxone, 143
- nausea, 72, *see also*
 postoperative nausea and
 vomiting
 physiology, 137
- neostigmine, 62–3, 71
 postoperative pain
 management, 123
- nerve blocks *see* neuromuscular
 blockers; peripheral
 blocks; regional
 anesthesia
- neuraxial blocks, 78–81
- neuroleptics, 142
- neurologic diseases, 29
 anesthesia, 97

Index

- neuromuscular blockers, 39,
61–3, 70–1, 76, 159, 166,
see also loco-regional
techniques
recipe, 159
reversal agents, 62–3
- newborn infants, 18
- premature, 18–19
- nicotine, postoperative pain
management, 123
- nitrous oxide, 57, 69 *see also*
inhalational drugs
children, 89–90
pharmacodynamics, 41–2
pharmacokinetics, 40–1
recipes, 154–5, 156
supplementation, versus
TIVA, 164
- NK1 inhibitors, 143
- NMDA-receptor antagonists,
119–20
- nonopioid analgesics, 61, 107,
109–24 *see also specific*
analgesics
adjuvants, 122–4
 α 2-adrenergic receptor
agonists, 121–2
calcium channel blockers,
120–1
clinical application, 124–6
glucocorticoids, 115–19
local anesthesia, 110
NMDA-receptor
antagonists, 119–20
nonsteroidal anti-
inflammatory drugs
(NSAIDs), 111–15
paracetamol, 110–11
principles, 109
- nonsteroidal anti-inflammatory
drugs (NSAIDs),
111–15
preoperative administration,
125
side-effects, 112–13,
114–15
- obesity, 24–5, 163
anesthesia and, 93–5
premedication and, 94
- older patients *see* elderly
patients
- ondansetron, 142
- opioid antagonists, 64
- opioids, 42, 59–61, 70 *see also*
intravenous drugs
combination with propofol,
50–2
elderly patients, 91
interactions, 50–2
postoperative pain
management, 109
recipes, 154–9
sedation, 86–7
side-effects, 49–50
- oral contraceptives, 26
- organization, 7–10, *see also*
ambulatory unit
- orthopedic surgery, 162
- outpatient consultation, 1–2,
151
- oxycodone, 60
- pacemaker, 23
anesthesia and, 92–3
- pain *see* postoperative pain
- paracetamol, 110–11
preoperative administration,
125
side-effects, 111
- paravertebral anesthesia, 79
- patient formulary, 30–1
- patient selection, 16–29
acute disease, 27
age, 18–20
airway or pulmonary disease,
20–1
alcohol or drug abuse,
25–6
allergy, 29
anesthesia problems, 29
breastfeeding patients, 28
cardiovascular disease, 91–3
diabetes mellitus, 25
epileptic patients, 29
general considerations,
16–18
kidney disease, 28
liver disease, 28
neurologic diseases, 29
obese patients, 24–5
pregnant patients, 27
psychiatric patients, 27
regular medications, 26–7
rheumatic disorders, 28–9
thyroid disorders, 28
- peripheral blocks, 81–3
early discharge safety with
long-acting blocks, 83
single lower-extremity
surgery, 81–2
upper-limb surgery, 82
- personnel, 12–13
- pharmacodynamics, 38, 46
inhalational drugs, 41–2
intravenous drugs, 46–50
strength of effect, 48–9
timing of effect, 46–8
type of effect, 49–50
- pharmacokinetics, 38
inhalational drugs, 39–41
intravenous drugs, 43–6
- pharmacology, 39 *see also*
pharmacodynamics;
pharmacokinetics
general aspects, 38–9
- physical requirements, 11–12
- plasma target concentration, 53
- plasma target control infusion
(TCI) system, 53
versus effect site TCI system,
55
- PONV *see* postoperative nausea
and vomiting
- post-discharge care, 150–1
next-day phone call, 150–1
on-call availability, 150
outpatient consultation, 151
patient questionnaire, 151
- postoperative care, 146, *see also*
postoperative nausea and
vomiting; postoperative
pain; post-discharge care
agitation, 147
anxiety, 147
hospital care, 148–9
immediate, in postoperative
care unit, 148–8
pruritus, 146
shivering, 146
somnolence, 147
urinary retention, 146–7
- postoperative care unit,
11–12
discharge criteria, 148
documentation, 14
immediate postoperative
care, 148–8
personnel, 13

Index

- postoperative nausea and vomiting, 136–7, *see also* anti-emetic drugs
 drug treatment principles, 140–1
 etiology and risk factors, 137–9
 loco-regional technique
 benefits, 72
 non-drug treatment and prophylaxis, 139–40
 physiology, 137
 prophylaxis approach, 143–4
 risk factors, 138
 treatment approach, 144
 postoperative pain, 106–27, *see also specific analgesics*
 loco-regional technique
 benefits, 72
 medication approach, 127
 nonopioid analgesics, 109–24
 nonpharmacologic approaches, 124
 opioids, 109
 pain physiology, 106–7
 peroperative management, 125–6
 postoperative management, 126
 preoperative management, 125
 pre-emptive analgesia, 106–7, 126
 pregabalin, 120–1
 pregnancy, 27
 anesthesia, 96
 premature infants, 18–19
 premedication, 98–9
 anticoagulation, 98–9
 glucocorticoids, 99
 obese patients, 94
 recipe, 152–3
 preoperative evaluation, 20
 preoperative information, 30–5
 from the patient, 30–1
 from the physician, 31–2
 to patient, 32–5
 preoperative medication *see* premedication
 pretreatment, 15
 procedure selection, 15–16
 propacetamol, 111
 propofol, 58–9, 152, 167 *see also* intravenous drugs
 children, 89, 90, 160
 combination with opioids, 50–2
 elderly patients, 90–1
 interactions, 43, 50–2, 58
 pharmacokinetics, 44
 sedation, 73, 86
 side-effects, 50, 73
 target control infusion, 55–6
 pruritus, 146
 psychiatric patients, 27
 anesthesia, 96
 psychoprophylaxis, 124
 pulmonary disease, 20–1
 ASA III pulmonary/airway disease patients, 91
 preoperative information, 31
 quality, 4–5
 loco-regional techniques, 72–3
 success criteria, 176–7
 questionnaire, 151
 regional anesthesia *see also* loco-regional techniques
 regional anesthesia, 13, 71–3, 88
 definition, 71
 indications, 84–5
 intravenous regional anesthesia, 83
 procedures, 77
 remifentanyl, 39, 51, 59–60, 70, 152 *see also* intravenous drugs; opioids
 children, 160
 hyperalgesia, 60, 70, 126
 intubation and, 71
 sedation, 73, 86
 side-effects, 73
 target control infusion, 55
 renal disease *see* kidney disease
 respiratory infections, 20, *see also* pulmonary disease
 respiratory side-effects, 49–50
 revascularization, 22
 reversal agents, 62–3, 71
 rheumatoid arthritis, 28–9
 anesthesia, 97
 preoperative information, 31
 rocuronium, 62, 71
 ropivacaine, 74, 80
 runny nose in children, 19
 safety, 3–4
 loco-regional techniques, 72
 requirements, 11
 success criteria, 176
 sedation, 13, 72–3, 85–6, 122
 children, 88, 159–61
 monitoring, 87
 sedative drug selection, 86–7
 side-effects, 73
 self-registration formulary, 30–1
 serotonin antagonists, 142
 sevoflurane, 57, 68 *see also* inhalational drugs
 children, 90
 pharmacodynamics, 41–2
 pharmacokinetics, 40–1
 shivering, 146
 side-effects
 circulatory effects, 50
 glucocorticoids, 118
 information for patient, 33, 34–5
 NSAIDs, 112–13, 114–15
 paracetamol, 111
 respiratory effects, 49–50
 sedation, 73
 sleep apnea syndrome (SAS), 21, 91
 children, 19
 obese patients, 93
 preoperative information, 31
 smoking, 20
 obese patients, 93
 sodium channel blockers, 121
 somnolence, 147
 spinal anesthesia, 79–81
 staff satisfaction, 6, 177–8
 standards, 11
 statins, 27
 strength of effect, 48–9
 success criteria, 176–8
 cost-efficacy, 177
 patient quality, 176–7
 patient safety, 176
 staff satisfaction, 177–8
 sufentanil, 51, 60
 sugammadex, 63, 71
 suxamethonium, 62, 71
 $T_{1/2}$ context-sensitive, 44
 $T_{1/2}$ steady-state, 44

Index

- target control infusion (TCI),
 - 52–6, 69–70, 166–7
 - logic of, 52–4
 - models, 55–6
 - propofol, 55–6
 - recipes, 152–5
 - remifentanyl, 55
- thiopentone, 58
- thrombosis prophylaxis,
 - 98–9
- thyroid disorders, 28
 - anesthesia and, 97
- time to peak effect, 46–8
- tonsillectomy, 161
- total intravenous anesthesia (TIVA), 164 *see also*
 - intravenous anesthesia;
 - intravenous drugs
- development of,
 - 166–7
- drugs and adjuncts, 166
- versus inhalational anesthesia, 165
- versus nitrous oxide
 - supplementation, 164
- transient neurologic symptoms (TNS),
 - 79–80
- ultrasound-guided procedures, 74
 - nerve blocks, 82
- upper-limb surgery, 82
- urinary retention, 146–7
- vecuronium, 62
- vomiting, 72, *see also*
 - postoperative nausea and vomiting
 - physiology, 137
- warfarin, 24
- wounds, local anesthetic infusion, 74